U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Surveillance: Post Drug-Approval Activities
  1. Guidance, Compliance, & Regulatory Information

Surveillance: Post Drug-Approval Activities

A vital part of CDER's mission is to monitor the safety and effectiveness of drugs that are currently available to the American people.  To meet this goal, FDA has in place postmarketing programs that monitor marketed human medical products for unexpected adverse events. These programs alert the Agency to potential threats to the public health.  Agency experts then identify the need for preventive actions, such as changes in product labeling information and, rarely, re-evaluation of an approval decision. 



Back to Top